A Study to Establish a Registry of Guardant360® Use and Outcomes In People With Advanced Cancer

Overview

Información sobre este estudio

The purpose of this registry is to collect data that describes the characteristics of people with advanced cancer for whom the Guardant360 assay is ordered and to observe their clinical outcomes after receiving their results.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

General Inclusion Criteria:

  • 18 Years of age or older.
  • Ability to provide written informed consent.
  • Blood collected for the most recent Guardant360 test within 8 weeks prior to enrollment.

General Exclusion Criteria:

  • Pregnancy at the time of the qualifying Guardant360 blood collection.
  • History of the allogeneic organ or tissue transplant Module 1 (Non-Small Cell Lung Cancer).

Inclusion Criteria:

  • NSCLC, confirmed by histology or cytology.
  • Advanced disease, defined as: stage IIIB or IV NSCLC at the time of the qualifying Guardant360 blood collection; or for subjects with an initial diagnosis of Stage I-IIIA disease, NSCLC that is recurrent or metastatic at the time of the qualifying Guardant360 blood collection.
  • One of the following conditions at the time of the qualifying Guardant360 blood collection:
    •  Noprior systemic therapy for advanced disease; OR
    •  All three of the following conditions:
      • A history of prior systemic therapy for advanced disease;
      • Disease progression within the previous four weeks; and
      • No new systemic therapy for advanced disease.

Exclusion Criteria:

  • Subjects with a diagnosis or history of any cancer involving the lung that is not classified as NSCLC, including but not limited to small cell carcinoma, neuroendocrine or carcinoid tumor, lymphoma, mesothelioma, metastatic non-lung carcinoma, or cancer of unknown primary.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Jacksonville, Fla.

Investigador principal de Mayo Clinic

Yanyan Lou, M.D., Ph.D.

Cerrado para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publicaciones

Publications are currently not available
.
CLS-20493131

Mayo Clinic Footer